Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shaanxi Kanghui Pharma Completes $52 Million Shanghai IPO

publication date: Apr 21, 2017
Shaanxi Kanghui Pharmaceutical raised $52 million in a Shanghai exchange IPO. Founded in 2009 and headquartered in Xianyang, Kanghui has developed more than 100 products in a number of therapeutic areas. The company recorded a 2016 operating profit of $10 million on revenues of $55 million. Kanghui makes 16 exclusive products, which it sells to more than 2,000 China hospitals, and owns 19 patents. The online portion of the IPO received offers for almost 4000 times the number of shares available. More details....

Stock Symbol: (SHA: 603139)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital